TMCnet News
Senseonics Announces Aetna's Positive Coverage Decision for EversenseSenseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that Aetna, the third largest commercial health plan provider in the United States, is providing coverage for Eversense, effective immediately. Aetna's plan provides coverage for approximately 22 million lives in the United States. This recent coverage decision adds to the growing body of payers processing claims and paying for Eversense in the U.S. "We are pleased that one of the largest national payers in the U.S. is now covering Eversense, and that Aetna recognizes the value of CGM and the value Eversense can bring to the market in terms of patient adherence," said Tim Goodnow, President and Chief Executive Officer of Senseonics. "We believe this coverage decision represents a major milestone and has the potential to facilitate broad patient and physician access to Eversense in the U.S." About Eversense The Eversese® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a physician. The Eversense CGM System is a prescription device; patients should talk to their doctor to learn more. For important safety information, see https://eversensediabetes.com/safety-info/. About Senseonics Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe. For more information on Senseonics, please visit www.senseonics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005926/en/ |
